Tudor Investment Corp ET AL Buys Shares of 70,000 Alpha Cognition, Inc. (NASDAQ:ACOG)

Tudor Investment Corp ET AL purchased a new position in shares of Alpha Cognition, Inc. (NASDAQ:ACOG - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 70,000 shares of the company's stock, valued at approximately $412,000. Tudor Investment Corp ET AL owned approximately 0.44% of Alpha Cognition at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. National Bank of Canada FI purchased a new stake in Alpha Cognition in the 4th quarter worth approximately $69,000. MYDA Advisors LLC purchased a new position in Alpha Cognition in the 4th quarter worth approximately $589,000. Aristides Capital LLC purchased a new stake in Alpha Cognition in the 4th quarter valued at $1,178,000. ADAR1 Capital Management LLC acquired a new position in shares of Alpha Cognition during the 4th quarter valued at about $1,204,000. Finally, Boothbay Fund Management LLC purchased a new stake in Alpha Cognition in the 4th quarter valued at about $1,284,000.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ACOG shares. Raymond James raised Alpha Cognition to a "moderate buy" rating in a research report on Tuesday, March 25th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Alpha Cognition in a research report on Monday, March 31st.

Alpha Cognition Price Performance

Shares of ACOG traded up $0.02 during mid-day trading on Monday, hitting $7.45. 26,215 shares of the company's stock were exchanged, compared to its average volume of 81,460. The company has a 50 day simple moving average of $5.25. Alpha Cognition, Inc. has a fifty-two week low of $3.75 and a fifty-two week high of $8.61. The stock has a market cap of $119.35 million, a price-to-earnings ratio of -2.91 and a beta of 2.48.

Alpha Cognition (NASDAQ:ACOG - Get Free Report) last posted its quarterly earnings results on Monday, March 31st. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.03).

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.